M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors BioPharma DiveThe Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioPharma Dive The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersNext: Bayer wins MHRA approval for Kerendia in heart failure Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
